Proactive Investors - Run By Investors For Investors

Circassia Pharmaceuticals upbeat on growth prospects as it guides on revenues and costs

Ahead of a meeting to approve its move to AIM, the speciality pharma, which is focused on respiratory disease, told shareholders it had a healthy cash cushion of £41mln
lung via x-ray
Circassia is a speciality pharma focused on respiratory disease

Circassia Pharmaceuticals PLC (LON:CIR) said its cost containment efforts were showing results as it gave an upbeat assessment of the company’s growth prospects and provided revenue guidance for the 12 months just gone.

Ahead of a meeting to approve its move to AIM, the speciality pharma, which is focused on respiratory disease, told shareholders it had a healthy cash cushion of £41mln. At the meeting, 100% of the shareholders voting approved the switch to AIM.

READ: Circassia Pharmaceuticals exercises US option over lung disease drug

However, keeping a lid on expenditure meant the net cash outflow was less than £20mln last year. Turnover, meanwhile, was in the order of £48mln-£52mln.

While the assessment of the prospects for 2019 remained unchanged, Circassia said it saw “significant opportunities for strong sales growth”.

Growth drivers

Drivers will include Tudorza, the inhaler for chronic lung disease, after it added the full US rights to the drug, and China, where the business now has a direct sales operation.

The company hopes to have regulatory sign-off for Duaklir by the end of the first quarter, which would become part of a product set sold by a team focused solely on treatments for chronic obstructive pulmonary disease (COPD).

"Circassia continued to make progress during 2018, and with our cost containment efforts showing results and revenues growing we look forward to continuing our trajectory towards self-sustainability,” said chief executive Steve Harris.

“We look forward to the coming year, as we roll out our expanded sales force in China and plan to take full control of Tudorza and launch Duaklir, once approved, in the United States."

As followers of the group already know, it must make option and deferred payments totalling £95mln (US$120mln). It said plans to pay the sums via “third-party funding, or through a loan facility provided by AstraZeneca under the companies' agreement if this is unavailable”.

In a note to clients, analysts at Peel Hunt commented: "Today’s top line disappointment is backward-looking; the balance sheet is robust and the upbeat outlook and March FDA catalysts suggest strong value remains." 

However, the City broker still placed its estimates and target price and rating for Circassia to 'under review', from 'buy', pending further interaction with the company.

In afternoon trading, Circassia shares were 12.7% lower at 48.20p.

 -- Adds analyst comment, share price -- 

View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use